Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL21776630 | 0.99 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL7298547 | 0.92 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL6857533 | 0.89 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL4363347 | 0.88 | ALDH1A1 (0.44) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL8861128 | 0.88 | ALDH1A1 (0.40) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL2121837 | 0.87 | HCRTR1 (0.35) | ALDH1A1HPGDTSHRKMT2ANPSR1 | |
| SCHEMBL1969215 | 0.87 | CYP3A4 (0.34) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL2626704 | 0.86 | HPGD (0.40) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL7308680 | 0.85 | KDM4E (0.30) | ALDH1A1HPGDKDM4EHTTRECQL | |
| SCHEMBL7883597 | 0.84 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4EHTTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039279-A | Synthesis process of trityl olmesartan medoxomil | 浙江华洋药业有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-116813552-A | Recovery and purification process of olmesartan intermediate impurities | 江苏阿尔法药业股份有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-112337419-B | Preparation method of 4- (1-hydroxy-1-methylethyl) -2-propylimidazole-5-carboxylic acid ethyl ester | 浙江花蝶染料化工有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-112337419-A | Preparation method of 4- (1-hydroxy-1-methylethyl) -2-propylimidazole-5-carboxylic acid ethyl ester | 浙江花蝶染料化工有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-111253375-A | Preparation and purification method of key intermediate of olmesartan medoxomil | 山东新华制药股份有限公司 | 2020-06-09 | — | — | CN | claimed |
| EP-2173741-B1 | A PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | LEK PHARMACEUTICALS (SI) | 2013-10-02 | — | — | EP | claimed |
| US-8048904-B2 | Process for the preparation of olmesartan medoxomil | MATRIX LABORATORIES LTD. (IN) | 2011-11-01 | — | — | US | claimed |
| US-20110224271-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | LEK PHARMACEUTICALS D.D. (SI) | 2011-09-15 | — | — | US | claimed |
| WO-2011007368-A2 | AN IMPROVED PROCESS FOR PREPARATION OF OLMESARTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-01-20 | — | — | WO | claimed |
| EP-2173741-A1 | A PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | Lek Pharmaceuticals D.D. (SI) | 2010-04-14 | — | — | EP | claimed |
| US-20090281327-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX PHARMACORP PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | claimed |
| EP-2036904-A1 | A process for the preparation of olmesartan medoxomil | LEK Pharmaceuticals D.D. (SI) | 2009-03-18 | — | — | EP | claimed |
| WO-2009019304-A1 | A PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | LEK PHARMACEUTICALS D.D. (SI) | 2009-02-12 | — | — | WO | claimed |
| EP-1916246-A2 | An improved process for the preparation of olmesartan medoxomil | Cadila Pharmaceuticals Limited (IN) | 2008-04-30 | — | — | EP | claimed |
| WO-2007148344-A2 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MATRIX LABORATORIES LIMITED (IN) | 2007-12-27 | — | — | WO | claimed |
| CN-119039279-A | Synthesis process of trityl olmesartan medoxomil | 浙江华洋药业有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119039279-A | Synthesis process of trityl olmesartan medoxomil | 浙江华洋药业有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-5459148-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0603001-A1 | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease | SANKYO COMPANY LIMITED (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224271-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | THOP1, CYP4A11, THPO | ALDH1A1 2308/4885HPGD 1550/4885KDM4E 1381/4885 |
| US-20090281327-A1 | PROCESS FOR THE PREPARATION OF OLMESARTAN MEDOXOMIL | MED1, TET1, AGTR1 | ALDH1A1 805/4885HPGD 1340/4885KDM4E 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.